Replimune Group, Inc. (REPL) shareholders
REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q/A on Nov 6, 2026Score 1/30
$21.78−1.50 (-6.44%)
Close on Nov 11, 2026Market cap $2.06BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
95M of 95M shares
Institutional holders
199
72 new, 51 sold out
Net institutional buying
14M
In Q2 2026
Insider trades, 12 months
0 buys · 19 sales
Net sold $2.45M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Julian C. Baker Joint filing with Baker Bros. Advisors LP (11.80%), Baker Bros. Advisors (GP) LLC (11.80%) and 1 more | 11,075,336 | 11.80% | 13D (active) amendment | Aug 9, 2026 |
| Roderick Wong Joint filing with RTW Investments, LP (8.90%) | 7,356,916 | 8.90% | 13G (passive) amendment | Mar 31, 2026 |
| Ridgeback Capital Management LLC Joint filing with Ridgeback Capital Investments L.P. (8.70%), Ridgeback Capital Investments LLC (8.70%) | 7,310,656 | 8.70% | 13G (passive) amendment | Jun 30, 2026 |
| Aaron Cowen Joint filing with Montanova Capital, LLC (7.90%), Averill Master Fund, Ltd. (6.70%) | 6,609,000 | 7.90% | 13G (passive) amendment | Jul 30, 2026 |
| RTW Investments, LP Joint filing with Roderick Wong (8.20%) | 6,395,732 | 8.20% | 13G (passive) | Sep 30, 2025 |
| Ridgeback Capital Investments LLC Joint filing with Ridgeback Capital Investments L.P. (7.60%), Ridgeback Capital Management LLC (7.60%) | 6,252,651 | 7.60% | 13G (passive) | May 14, 2026 |
| Redmile Group, LLC Joint filing with Jeremy C. Green (6.40%) | 4,898,527 | 6.40% | 13G (passive) amendment | Mar 31, 2025 |
| BlackRock, Inc. | 4,538,487 | 7.70% | 13G (passive) amendment | Dec 31, 2023 |
| Point72 Capital Advisors, Inc. Joint filing with Point72 Asset Management, L.P. (5.70%), Steven A. Cohen (5.70%) | 4,462,500 | 5.70% | 13G (passive) | Jul 30, 2025 |
| The Goldman Sachs Group, Inc. Joint filing with Goldman Sachs & Co. LLC (5.30%) | 4,418,838 | 5.30% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of REPL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 11,045,336 | 11.65% | $122.27M | – | 0.61% |
| BlackRock, Inc. | 8,958,535 | 9.45% | $99.17M | +2,719,296 | 0.00% |
| Rtw Investments, LP | 7,411,581 | 7.82% | $82.05M | +54,665 | 0.70% |
| Ridgeback Capital Investments L.P. | 7,310,656 | 7.71% | $80.93M | New | 100.00% |
| Goldman Sachs Group Inc | 4,541,018 | 4.79% | $50.27M | +2,263,742 | 0.00% |
| State Street Corp | 4,440,144 | 4.68% | $49.15M | +657,907 | 0.00% |
| Suvretta Capital Management, LLC | 4,389,836 | 4.63% | $48.60M | +168,000 | 0.89% |
| Boxer Capital Management, LLC | 3,983,000 | 4.20% | $44.09M | +2,808,000 | 3.32% |
| Vanguard Capital Management LLC | 2,896,004 | 3.05% | $32.06M | +136,884 | 0.00% |
| Fcpm Iii Services B.V. | 2,808,368 | 2.96% | $31.09M | – | 4.14% |
| Aqr Capital Management LLC | 2,566,241 | 2.71% | $28.41M | +2,310,746 | 0.01% |
| Logos Global Management LP | 2,500,000 | 2.64% | $27.68M | New | 1.19% |
| Jane Street Group, LLC | 2,322,545 | 2.45% | $25.71M | +1,894,400 | 0.00% |
| Erste Asset Management GmbH | 2,120,000 | 2.24% | $23.74M | – | 0.18% |
| Geode Capital Management, LLC | 2,035,187 | 2.15% | $22.53M | +233,662 | 0.00% |
| D. E. Shaw & Co., Inc. | 1,789,964 | 1.89% | $19.81M | −546,564 | 0.01% |
| Price T Rowe Associates Inc /Md/ | 1,620,963 | 1.71% | $17.95M | −6,500,470 | 0.00% |
| Opaleye Management Inc. | 1,384,993 | 1.46% | $15.33M | New | 1.39% |
| Toronto Dominion Bank | 1,275,000 | 1.34% | $14.11M | −316,030 | 0.02% |
| UBS Group AG | 1,128,276 | 1.19% | $12.49M | +547,066 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 199 | 95M | 100.0% | 72 / 72 | 44 / 51 | 33M | 19M |
| Q1 2026 | 180 | 81M | 85.5% | 46 / 62 | 49 / 29 | 17M | 12M |
| Q4 2025 | 165 | 80M | 84.1% | 36 / 58 | 52 / 32 | 19M | 22M |
| Q3 2025 | 163 | 83M | 87.5% | 38 / 61 | 47 / 49 | 26M | 24M |
| Q2 2025 | 174 | 81M | 85.5% | 33 / 51 | 64 / 24 | 6M | 7M |
| Q1 2025 | 167 | 82M | 86.6% | 26 / 62 | 49 / 15 | 8M | 4M |
| Q4 2024 | 157 | 78M | 82.2% | 34 / 65 | 33 / 20 | 16M | 8M |
| Q3 2024 | 144 | 70M | 74.0% | 23 / 55 | 41 / 27 | 14M | 10M |
| Q2 2024 | 149 | 71M | 75.0% | 28 / 60 | 45 / 27 | 18M | 19M |
| Q1 2024 | 150 | 73M | 76.6% | 29 / 58 | 36 / 19 | 10M | 8M |
| Q4 2023 | 140 | 71M | 74.7% | 43 / 53 | 31 / 30 | 30M | 16M |
| Q3 2023 | 127 | 57M | 60.1% | 9 / 51 | 42 / 23 | 7M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
141 funds held REPL in Q2 2026, 58% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of REPL | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,754,492 | 2.91% | $30.49M | 0.28% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,072,994 | 2.19% | $22.95M | 0.03% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 1,972,684 | 2.08% | $21.84M | 0.00% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 1,514,745 | 1.60% | $13.16M | 0.25% | May 31, 2026 |
| BlackRock Advantage Small Cap Core Fund | 870,064 | 0.92% | $7.56M | 0.14% | May 29, 2026 |
| Fidelity Small Cap Index Fund | 865,966 | 0.91% | $9.70M | 0.03% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 854,089 | 0.90% | $9.45M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 737,491 | 0.78% | $8.16M | 0.06% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 718,800 | 0.76% | $7.96M | 0.05% | Jun 30, 2026 |
| Artisan International Small-Mid Fund | 603,185 | 0.64% | $6.68M | 0.26% | Jun 30, 2026 |
| iShares Biotechnology ETF | 537,807 | 0.57% | $5.95M | 0.07% | Jun 30, 2026 |
| Invesco Dorsey Wright Healthcare Momentum ETF | 405,048 | 0.43% | $4.54M | 1.93% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 390,862 | 0.41% | $3.40M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 367,848 | 0.39% | $3.20M | 0.02% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 356,912 | 0.38% | $3.10M | 0.01% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Sushil Patel | Chief Executive Officer, Director | 708,151 | 0.75% | Aug 12, 2026 |
| Emily Luisa Hill | Chief Financial Officer | 215,852 | 0.23% | Aug 19, 2026 |
| Andrew Schwendenman | Chief Accounting Officer | 99,425 | 0.10% | Aug 12, 2026 |
| Konstantinos Xynos | Chief Medical Officer | 224,215 | 0.24% | Aug 12, 2026 |
| Christopher Sarchi | Chief Commercial Officer | 180,962 | 0.19% | Jun 3, 2026 |
| Joseph P. Slattery | Director | 1,467 | 0.00% | Nov 10, 2026 |
| Kapil Dhingra | Director | 21,669 | 0.02% | Nov 3, 2026 |
| Philip Astley-Sparke | Director | 1,362,414 | 1.44% | Aug 24, 2026 |
| Julian Baker | Director, 10% owner | – | – | Aug 11, 2026 |
| Bros. Advisors Lp Baker | Director, 10% owner | – | – | Aug 11, 2026 |
| Bros. Advisors (GP) LLC Baker | Director, 10% owner | – | – | Aug 11, 2026 |
| Brothers Life Sciences LP Baker | Director, 10% owner | – | – | Aug 11, 2026 |
| Felix Baker | Director, 10% owner | 10,116,095 | 10.67% | Aug 11, 2026 |
| 667, L.P. | Director, 10% owner | – | – | Aug 11, 2026 |
| Paolo Pucci | Director | – | – | Apr 7, 2026 |
| Madhavan Balachandran | Director | – | – | Apr 7, 2026 |
| Dieter Weinand | Director | – | – | Apr 7, 2026 |
| Christy J. Oliger | Director | – | – | Apr 7, 2026 |
| Veleka Peeples-Dyer | Director | – | – | Apr 7, 2026 |
| Michael Goller | Director | – | – | Mar 7, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Joseph P. Slattery Director | Nov 9, 2026 | Sale | −5,200 | $21.80 | $113.36K | 1,467 |
| Kapil Dhingra Director | Nov 2, 2026 | Sale | −21,500 | $19.00 | $408.50K | 21,669 |
| Kapil Dhingra Director | Nov 2, 2026 | Option exercise | +43,169 | $1.75 | $75.55K | 43,169 |
| Philip Astley-Sparke Director | Aug 20, 2026 | Gift | −50,000 | – | – | 1,362,414 |
| Emily Luisa Hill Chief Financial Officer | Aug 17, 2026 | Sale | −9,256 | $14.28 | $132.18K | 215,852 |
| Emily Luisa Hill Chief Financial Officer | Aug 10, 2026 | Sale | −11,448 | $12.97 | $148.48K | 225,108 |
| Sushil Patel Chief Executive Officer, Director | Aug 10, 2026 | Sale | −39,341 | $12.97 | $510.25K | 708,151 |
| Andrew Schwendenman Chief Accounting Officer | Aug 10, 2026 | Sale | −7,632 | $12.97 | $98.99K | 99,425 |
| Konstantinos Xynos Chief Medical Officer | Aug 10, 2026 | Sale | −11,447 | $12.97 | $148.47K | 224,215 |
| Christopher Sarchi Chief Commercial Officer | Jun 1, 2026 | Sale(10b5-1 plan) | −12,000 | $9.24 | $110.88K | 180,962 |
| Philip Astley-Sparke Director | May 18, 2026 | Sale | −17,657 | $5.08 | $89.70K | 1,412,414 |
| Sushil Patel Chief Executive Officer, Director | May 18, 2026 | Sale | −37,324 | $5.08 | $189.61K | 747,492 |
| Christopher Sarchi Chief Commercial Officer | May 18, 2026 | Sale | −8,626 | $5.08 | $43.82K | 192,962 |
| Emily Luisa Hill Chief Financial Officer | May 18, 2026 | Sale | −7,812 | $5.08 | $39.68K | 236,556 |
| Andrew Schwendenman Chief Accounting Officer | May 18, 2026 | Sale | −7,894 | $5.08 | $40.10K | 107,057 |
| Konstantinos Xynos Chief Medical Officer | May 18, 2026 | Sale | −14,023 | $5.08 | $71.24K | 235,662 |
| Christopher Sarchi Chief Commercial Officer | Apr 2, 2026 | Sale(10b5-1 plan) | −6,500 | $8.01 | $52.07K | 151,588 |
| Konstantinos Xynos Chief Medical Officer | Apr 1, 2026 | Award | +50,000 | – | – | 249,685 |
| Emily Luisa Hill Chief Financial Officer | Apr 1, 2026 | Award | +50,000 | – | – | 244,368 |
| Christopher Sarchi Chief Commercial Officer | Apr 1, 2026 | Award | +50,000 | – | – | 201,588 |
| Andrew Schwendenman Chief Accounting Officer | Apr 1, 2026 | Award | −36,667 | – | – | 114,951 |
| Sushil Patel Chief Executive Officer, Director | Apr 1, 2026 | Award | +251,240 | – | – | 784,816 |
| Philip Astley-Sparke Director | Apr 1, 2026 | Award | +50,000 | – | – | 1,430,071 |
| Philip Astley-Sparke Director | Feb 18, 2026 | Gift | −25,000 | – | – | 1,380,071 |
| Sushil Patel Chief Executive Officer, Director | Dec 19, 2025 | Award | +200,000 | – | – | 533,576 |
| Konstantinos Xynos Chief Medical Officer | Dec 19, 2025 | Award | +60,000 | – | – | 199,685 |
| Andrew Schwendenman Chief Accounting Officer | Dec 19, 2025 | Award | +10,000 | – | – | 78,284 |
| Christopher Sarchi Chief Commercial Officer | Dec 19, 2025 | Award | +35,000 | – | – | 158,088 |
| Emily Luisa Hill Chief Financial Officer | Dec 19, 2025 | Award | +60,000 | – | – | 194,368 |
| Kapil Dhingra Director | Dec 9, 2025 | Option exercise | +3,169 | $1.75 | $5.55K | 3,169 |
| Kapil Dhingra Director | Dec 9, 2025 | Sale | −3,169 | $10.40 | $32.96K | 0 |
| Sushil Patel Chief Executive Officer, Director | Dec 2, 2025 | Sale(10b5-1 plan) | −10,000 | $11.13 | $111.30K | 333,576 |
| Konstantinos Xynos Chief Medical Officer | Nov 17, 2025 | Sale | −7,248 | $9.10 | $65.96K | 139,685 |
| Christopher Sarchi Chief Commercial Officer | Nov 17, 2025 | Sale | −5,208 | $9.10 | $47.39K | 123,088 |
| Emily Luisa Hill Chief Financial Officer | Aug 15, 2025 | Sale | −9,154 | $5.37 | $49.16K | 134,368 |
| Andrew Schwendenman Chief Accounting Officer | May 20, 2025 | Sale | −3,287 | $8.05 | $26.46K | 68,284 |
| Emily Luisa Hill Chief Financial Officer | May 20, 2025 | Sale | −2,535 | $8.05 | $20.41K | 143,522 |
| Konstantinos Xynos Chief Medical Officer | May 20, 2025 | Sale | −7,952 | $8.06 | $64.09K | 146,933 |
| Sushil Patel Chief Executive Officer, Director | May 20, 2025 | Sale | −25,105 | $8.06 | $202.35K | 343,576 |
| Christopher Sarchi Chief Commercial Officer | May 20, 2025 | Sale | −3,749 | $8.05 | $30.18K | 128,296 |
| Philip Astley-Sparke Director | May 20, 2025 | Sale | −32,279 | $8.06 | $260.17K | 1,405,071 |
| Emily Luisa Hill Chief Financial Officer | Apr 1, 2025 | Award | +45,000 | – | – | 146,057 |
| Sushil Patel Chief Executive Officer, Director | Apr 1, 2025 | Award | +166,667 | – | – | 368,681 |
| Christopher Sarchi Chief Commercial Officer | Apr 1, 2025 | Award | +45,000 | – | – | 132,045 |
| Konstantinos Xynos Chief Medical Officer | Apr 1, 2025 | Award | +45,000 | – | – | 154,885 |
| Andrew Schwendenman Chief Accounting Officer | Apr 1, 2025 | Award | −33,333 | – | – | 71,571 |
| Sushil Patel Chief Executive Officer, Director | Dec 16, 2024 | Sale(10b5-1 plan) | −10,000 | $12.42 | $124.20K | 202,014 |
| Christopher Sarchi Chief Commercial Officer | Nov 18, 2024 | Sale | −5,207 | $10.78 | $56.13K | 87,045 |
| Konstantinos Xynos Chief Medical Officer | Nov 18, 2024 | Sale | −7,246 | $10.78 | $78.11K | 109,885 |
| Philip Astley-Sparke Executive Chairman, Director | Aug 30, 2024 | Gift | −50,000 | – | – | 1,437,350 |
| Emily Luisa Hill Chief Financial Officer | Aug 16, 2024 | Sale | −8,938 | $10.18 | $90.99K | 101,057 |
| Konstantinos Xynos Chief Medical Officer | Jun 7, 2024 | Sale(10b5-1 plan) | −15,881 | $7.50 | $119.11K | 117,131 |
| Colin Love Chief Operating Officer | May 16, 2024 | Sale | −17,615 | $6.47 | $113.97K | 777,345 |
| Christopher Sarchi Chief Commercial Officer | May 16, 2024 | Sale | −2,218 | $6.47 | $14.35K | 92,252 |
| Andrew Schwendenman Chief Accounting Officer | May 16, 2024 | Sale | −2,298 | $6.47 | $14.87K | 38,238 |
| Philip Astley-Sparke Executive Chairman, Director | May 16, 2024 | Sale | −37,928 | $6.47 | $245.39K | 1,487,350 |
| Konstantinos Xynos Chief Medical Officer | May 16, 2024 | Sale | −6,367 | $6.47 | $41.19K | 133,012 |
| Robert Coffin Director | May 16, 2024 | Sale | −11,464 | $6.47 | $74.17K | 1,821,872 |
| Sushil Patel Chief Executive Officer, Director | May 16, 2024 | Sale | −20,194 | $6.47 | $130.66K | 212,014 |
| Emily Luisa Hill Chief Financial Officer | Apr 1, 2024 | Award | +26,665 | – | – | 109,995 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
30.42%
25M shares short
Days to cover
8.3
At 3M shares a day
Change since last report
+6.2%
From 23M shares
Short volume, 20 days
52.4%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Replimune's stock actually held short. Settlement fails (shares not delivered on time) peaked at 17,998 shares on Aug 24, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Joseph P. Slattery Director | Nov 9, 2026 | 5,200 | $113.36K | Nov 9, 2026 | Exercised Shares |
| Paolo Pucci Director | Nov 3, 2026 | 138,700 | $2.83M | Nov 3, 2026 | Stock Option Exercise |
| Kapil Dhingra Director | Nov 2, 2026 | 16,500 | $292.88K | Nov 2, 2026 | Stock Options |
| Veleka Peeples-Dyer Director | Oct 30, 2026 | 10,000 | $167.23K | Oct 30, 2026 | Stock Option Exercise |
| Veleka Peeples-Dyer Director | Oct 28, 2026 | 12,000 | $154.74K | Oct 28, 2026 | Stock Option Exercise |
| Christopher Sarchi Officer | Apr 2, 2026 | 18,500 | $142.45K | Apr 2, 2026 | RSU Vesting |
| Kapil Dhingra Director | Dec 9, 2025 | 3,164 | $32.84K | Dec 9, 2025 | Stock Options |
| Sushil Patel Chief Strategy Officer | Dec 2, 2025 | 10,000 | $111.30K | Dec 2, 2025 | Stock Options |
| Sushil Patel Chief Strategy Officer | Dec 16, 2024 | 15,000 | $188.55K | Dec 16, 2024 | Rsetricted Stock Units |
| Konstantinos Xynos Officer | Jun 7, 2024 | 15,881 | $119.19K | Jun 7, 2024 | Rsetricted Stock Units |
| Pamela Esposito Officer | May 23, 2024 | 79,710 | $472.68K | May 23, 2024 | Stock Option Exercise |
| Pamela Esposito Officer | Jul 10, 2023 | 80,000 | $1.69M | Jul 10, 2023 | Stock Option Exercise |
| Sushil Patel Affiliate | Jun 13, 2023 | 23,710 | $556.00K | Jun 13, 2023 | RSU Vesting |
| Tanya Lewis Affiliate | Jun 13, 2023 | 22,486 | $527.30K | Jun 13, 2023 | RSU Vesting |
See a number that looks wrong?